Latest Regulatory News

Anteris Technologies has closed a $320 million capital raise, combining a $230 million public offering and a strategic private placement with Medtronic, to advance its DurAVR heart valve clinical trials and manufacturing growth.

Celsius Resources has released a Definitive Feasibility Study for its Maalinao-Caigutan-Biyog (MCB) Copper-Gold Project, confirming robust economics and a 35-year mine life. The study highlights strong returns, low operating costs, and a clear path to development in the Philippines.

Anteris Technologies Global Corp. has entered a material definitive agreement to raise approximately $320 million through a public offering and a strategic private placement with Medtronic’s subsidiary. The capital will support clinical trials and manufacturing expansion for its innovative heart valve technology.

DMC Mining Limited will be delisted from the ASX on 27 January 2026 following a two-year suspension, but the company remains committed to relisting pending key exploration licences in Guinea.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.

Liberty Metals has announced a significant discovery of high-grade monazite mineralisation rich in critical rare earth elements at its Paraiba Rutile and Monazite Project in Brazil, opening new avenues for exploration and processing.

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.

Arovella Therapeutics has filed an IND application for its lead CAR-iNKT therapy ALA-101, selected a CRO for its upcoming phase 1 trial, and secured $19.4 million in cash to fund clinical progress and pipeline expansion.

PYC Therapeutics has reported significant progress across its four RNA therapeutic programs targeting rare genetic diseases, supported by a strong cash position of $121 million at the end of 2025. Key clinical milestones and regulatory plans set the stage for upcoming trial readouts and potential market entry.

Clover Corporation has initiated an on-market acquisition of up to 3.26 million shares to satisfy future employee share plan vesting, aiming to reduce shareholder dilution from new share issuances.

Aura Energy has attracted a C$10 million investment from MMCAP and strategic partners, valuing its Swedish Häggån polymetallic project at C$50 million and spinning it into a new Canadian-listed entity.

Light & Wonder, Inc. has amended its credit agreement to introduce a new $2.13 billion tranche of term loans due in 2029, replacing prior debt and reducing borrowing costs. The move reflects a strategic refinancing amid its Nasdaq delisting process.